Rucaparib (4) – Rubraca®

Ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma, maintenance therapy after first-line therapy

Characteristics

Start date 15.12.2023 – Marketing authorisation: 15.11.2023
Resolution 06.06.2024
INN Rucaparib
Brand name Rubraca®
Pharm. company Pharmaand Deutschland GmbH
G-BA Procedure ID D-1031
ATC code L01XK03 PARP inhibitors (L01XK)
Therapeutic area Oncological diseases
Reason for procedure New therapeutic indication

Studies and Results

Adult female patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in remission (complete or partial) following completion of first-line platinum-based chemotherapy; Maintenance therapy

  • For maintenance therapy in adult female patients with advanced epithelial (FIGO stages III and IV) high-grade carcinoma of the ovaries, fallopian tubes or primary peritoneal carcinoma, who are in remission (complete or partial) following completion of first-line platinum-based chemotherapy, an additional benefit is not proven.
  • In summary, there are no suitable data available to enable an assessment of the additional benefit, which is why the additional benefit of rucaparib is not proven.

Courtesy translation only, please refer to the German original.

Associated procedures



<< List of all resolutions